BioAlliance Pharma announces:

New achievements in clonidine Lauriad™ clinical development,

Second product of its orphan oncology portfolio

Paris, April 17, 2012 – BioAlliance Pharma SA (Euronext Paris - BIO), a Company dedicated to specialty and orphan pharma products in oncology and supportive care, today announces new achievements in its phase II clinical trial with clonidine Lauriad™.

This trial, in which more that 30% of planned patients are already included, aims at evaluating the efficacy and tolerance of clonidine Lauriad™ in the prevention and the treatment of radio/chemotherapy-induced oral mucositis in patients with head and neck cancer. To date, the participating centers have not reported any particular toxicity related to the product and they confirm their interest in this study.

Thus, BioAlliance Pharma is planning to enlarge the trial, already ongoing in France, Germany and Spain, to 4 other European countries in the next weeks. This expansion to about 50 active centers will enable to accelerate the recruitment in the trial that should be finalized in 2013.

Oral mucositis is a particularly invalidating pathology occurring in 60% of patients treated with radio/chemotherapy for head and neck cancer. It may induce intense oral pain and eating disability requiring artificial nutritional support. 20 to 30% of patients have to be hospitalized and more than 10% of them require a modification or a stop of the radiotherapy treatment*. Radiotherapy-induced oral mucositis has currently no preventive cure.

" Clonidine Lauriad™, that has been granted the "orphan designation" in Europe last October, is a high potential asset of our "orphan oncology products" portfolio", declares Judith Greciet, CEO of BioAlliance Pharma. *"Beyond optimizing the product development, the expansion of our trial in Europe enables us to already involve a great number of specialists, part of our future prescriber network".*

** Trotti et al, 2003*

About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)
Sitavir® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status
Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Authorization for Phase III clinical trial
Clonidine Lauriad™ (mucositis): Phase II on going
AMEP™ (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Judith Greciet, COO
Tel +33 1 45 58 70 61
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com